NCT00828308 2022-03-08
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Brown University
Phase 2 Completed
Clinical Trials
11 trialsNCT00672009 2018-10-24
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Terminated
NCT00923130 2018-04-17
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00058084 2017-02-23
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00331643 2014-11-14
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00087139 2014-05-09
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00016393 2013-06-24
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00070096 2013-06-24
Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00182702 2013-03-25
Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00021099 2013-01-24
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00030992 2012-08-20
BMS 247550 to Treat Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed